Navigation Links
Haemacure's Human Fibrin Sealant Demonstrates Effectiveness in Skin Graft Fixation Proof-of-Concept Study for Burn Injury
Date:12/9/2008

HAE:TSX

Skin graft fixation for burn victims using fibrin sealant represents

multi-million dollar market opportunity for Company

MONTREAL, Dec. 9 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, disclosed today the positive results of a preclinical study conducted on the use of its proprietary lead product candidate, the human fibrin sealant Hemaseel(R)HMN, in skin graft fixation for burn victims.

"We are very excited with the results of this preclinical study, which suggest that Haemacure's fibrin sealant technology may provide a safe and effective alternative to staples and sutures and reduce discomfort of burn patients receiving skin grafts" said Joseph Galli, Chairman and CEO of Haemacure. "Skin graft fixation is the second new potential product indication based on the formulation of our lead hemostasis product candidate. This demonstrates again our commitment to leveraging our technology platform to meet major medical needs and position Haemacure as the only global, independent fibrin sealant-centric company", concluded Mr. Galli.

The results of this preclinical study strongly suggest that the use of Haemacure's fibrin sealant, with a reduced thrombin concentration, may provide advantages over staples and sutures, the current standard of care, when used to secure skin grafts to recipient wound sites. The use of staples or sutures in skin graft fixation for burn patients can often lead to post-operative complications such as wound infection, and create anxiety over pain during removal.

The objective of the study was to evaluate the effectiveness of tissue fixation, rather than hemostasis. As a result, the thrombin concentration of the fibrin sealant was reduced to provide additional time for the manipulation and positioning of the skin grafts. There were no alterations to any of the other components of the fibrin sealant.

The use of the fibrin sealant between the skin graft and the wound bed interface was shown to (1) provide adhesive qualities allowing fixation of the graft without the use of staples or sutures, (2) seal the tissue bed layer, thereby inhibiting seroma or hematoma formation without compromising the healing process, and (3) likely provide more even healing, resulting in a higher percentage of graft take with a more acceptable cosmetic outcome than using mechanical fixation.

Previous preclinical studies have demonstrated the effectiveness of Haemacure's fibrin sealant hemostasis formulation in preventing the formation of post-surgical adhesions. The ability to utilize the fibrin sealant hemostasis formulation for the additional indications of adhesion prevention and skin graft fixation is anticipated to reduce manufacturing and clinical risks and to significantly shorten time-to market, by as much as three to five years. Haemacure plans on conducting additional studies to support and confirm these findings.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first half of calendar 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on the use of fibrin sealant in aesthetics, adhesion prevention, combination with biomaterials, drug delivery, regenerative medecine, skin graft fixation for burn injuries, and wound healing. Haemacure has identified eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure is headquartered in Montreal, Canada and operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.


'/>"/>
SOURCE Haemacure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Human Genome Sciences to Sponsor Conference Call
2. Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8
3. CA$2.4 million toward gene therapy for human degenerative retinal diseases
4. NHS Human Services to Take Over Tri County Human Services Center
5. Saint Barnabas Medical Center Pioneers New Program Bringing Humanities and Humanism to Medicine
6. European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
7. MINRAD International, Inc. Announces Termination of RxElite Holdings Inc. as Anesthetics Distributor for the Human Market in United States
8. Public health and human rights: The work ahead of us
9. NCPA Statement on Tom Daschle Being Selected to Be Secretary of Health and Human Services Department
10. Bloomberg School awards Goodermote Humanitarian Award to Soledad OBrien
11. Bound by attention: Bringing rats and humans together
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Center for ... for caregivers of those affected by autism spectrum disorder (ASD) and other developmental disabilities. ... Seals Maine, will give parents and other caregivers the opportunity to share stories and ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... U.S. Surgeon ... interview with Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at ... learned that medicine is about more than making diagnoses and prescribing medicine,” he states. ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... ... 02, 2016 , ... More than half of American teens report losing their ... speaking with their child about sex related topics, less than 60 percent spoke about ... to announce the launch of its second edition of the “Sexual Wellness” campaign, aiming ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, ... through labeling, storing, shipping and disposal. The new version is a faster and ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016 Persistence Market Research ... its upcoming report titled, "Global Market Study on Cardiac Pacemaker: ... of -1.4% between 2016 and 2024". The global cardiac pacemaker ... and this is likely to decline to US$ 3923.8 ... cardiac pacemaker market is anticipated to exhibit a declining ...
(Date:12/2/2016)... December 2, 2016 According ... Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology ... Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to ... valued at USD 60.22 Billion in 2016. This ... of 5.5% during the forecast period (2016-2021) to ...
(Date:12/2/2016)... , Dec. 2, 2016  The Addiction Treatment ... Academy of Managed Care Pharmacy (AMCP), has released ... better address the opioid addiction crisis, including through ... (MAT). ATAG,s newly released paper, "The ... to Naloxone," addresses many issues around gaps and ...
Breaking Medicine Technology: